[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Pola-BR (polatuzumab vedotin, bendamustine, and rituximab) therapy received approval for...
Read More